Comparison of the Effectiveness of Different Assisted Reproductive Techniques (ART) in Couples with Unexplained Infertility

Abstract

Introduction Unexplained infertility, impacting 10-30% of couples, remains a significant challenge due to the absence of identifiable etiologies, complicating treatment decisions. Assisted reproductive technologies (ART) like IVF, IUI, and ICSI have become primary interventions, though their efficacy varies across patient subgroups. Objective of this StudyThis study aims to evaluate the clinical efficacy of IVF, IUI, and ICSI in managing unexplained infertility, considering patient demographics and prior ART outcomes, to guide evidence-based clinical decision-making. Matherials and methods A detailed literature search was undertaken across PubMed, Web of Science, and Embase to locate research on the adverse effects of monoclonal antibodies used in asthma management. The search covered English-language studies from the start of each database up to 2024. To ensure comprehensiveness, additional relevant studies were found by examining the reference lists of selected articles. Aim of the KnowledgeThe research seeks to clarify ART effectiveness in unexplained infertility, identifying optimal scenarios for each treatment type and assessing advancements that enhance reproductive outcomes while minimizing risks. ConclusionsThe analysis suggests IVF as the most effective option for complex cases, especially in advanced maternal age, though it involves higher risks. IUI is a lower-risk, cost-effective initial treatment, while ICSI is indicated for male factor infertility. Tailored ART strategies based on individual reproductive profiles are essential. SummaryThis study underscores the need for individualized ART approaches in unexplained infertility. IVF remains highly effective for challenging cases, while IUI and ICSI provide viable alternatives depending on patient-specific factors. Future research should aim to refine ART protocols to optimize success rates and minimize associated risks.